 Todos Medical Ltd revealed that all 31 patients enrolled to date in the Tollovir Phase 2 clinical trial in hospitalized coronavirus COVID-19 patients in Israel have completed their participation in the study, and the company is gearing up now for data locking and statistical analysis. The firms Tollovir drug candidate for COVID-19 uses a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. 